Durst Case Scenarios texasmonthly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasmonthly.com Daily Mail and Mail on Sunday newspapers.
孔雀羽_文学城博客 wenxuecity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wenxuecity.com Daily Mail and Mail on Sunday newspapers.
MedRhythms, in collaboration with Boston University, is launching a clinical trial of its pipeline asset MR-005 in Parkinson’s disease (PD).
In addition, the company is expanding its pipeline into aging with the development of its Aging Scientific Advisory Board (SAB). This follows MedRhythms’ announcement of the advancement of its pipeline into PD and multiple sclerosis (MS) in 2020 with the initiation of clinical trials and the development of MS and PD SABs.
MedRhythms, headquartered in Portland, Me, is a digital therapeutics company that builds direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury.
Portland health startup MedRhythms grows pipeline with new clinical trial, scientific board mainebiz.biz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mainebiz.biz Daily Mail and Mail on Sunday newspapers.
MedRhythms Launches Clinical Trial of Digital Therapeutic in Parkinson s Disease and Expands Pipeline to Aging
News provided by
Share this article
Share this article
PORTLAND, Maine, April 13, 2021 /PRNewswire/ MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, today announced the initiation of a multi-site clinical trial, in collaboration with Boston University and one of the world s leading hospitals, of its pipeline asset MR-005 in Parkinson s disease (PD) as well as the expansion of the company s pipeline into aging with the development of its Aging Scientific Advisory Board (SAB). This follows MedRhythms announcement of the advancement of its pipeline into PD and multiple sclerosis (MS) in 2020 with the initiation of clinical trials and the development of MS and PD SABs.